Iovance Biotherapeutics Reports Strong Q3 2025 Growth

Iovance Biotherapeutics ( (IOVA) ) has released its Q3 earnings. Here is a breakdown of the information Iovance Biotherapeutics presented to its investors.

Iovance Biotherapeutics, Inc. is a biotechnology company specializing in the development of tumor infiltrating lymphocyte (TIL) therapies aimed at treating cancer by leveraging the immune system’s natural ability to target and destroy cancer cells. The company is recognized for its innovative approach in cell therapy, particularly in solid tumors.

In its third-quarter 2025 earnings report, Iovance Biotherapeutics highlighted a 13% increase in quarterly revenue, reaching approximately $68 million. The company also reported a significant improvement in gross margin, now at 43%, attributed to enhanced operational efficiency and cost optimization strategies.

Key financial metrics revealed that product revenue was driven by U.S. sales of Amtagvi, which accounted for $58 million, and global sales of Proleukin, contributing $10 million. The company maintains a robust cash position of $307 million, expected to support operations into the second quarter of 2027. Iovance is also centralizing its manufacturing processes to further enhance gross margins.

Strategically, Iovance is expanding its commercial network for Amtagvi, with over 80 authorized treatment centers across the U.S., and has initiated global expansion with Health Canada’s approval for advanced melanoma treatment. The company is also advancing its pipeline, with promising data for lifileucel in non-small cell lung cancer and ongoing trials for other cancer indications.

Looking ahead, Iovance Biotherapeutics is poised for continued growth, with plans to centralize manufacturing and expand its treatment network. The company remains focused on advancing its pipeline and achieving regulatory approvals to meet significant unmet medical needs in cancer treatment.